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Background/Aims: The benefit of second-line chemother-
apy (SL) after failed first-line chemotherapy (FL) in patients 
with advanced pancreatic cancer has not yet been estab-
lished. We evaluated the clinical characteristics affecting 
the benefits of SL compared to best supportive care (BSC), 
identified the prognostic factors, and ultimately devised a 
model of clinical parameters to assist in making decision be-
tween SL and BSC after the failure of gemcitabine-based FL. 
Methods: The records of patients who received gemcitabine-
based FL for advanced pancreatic cancer at Yonsei University 
Hospital between January 2010 and December 2015 were 
retrospectively reviewed. Significant clinical parameters were 
assessed for their potential as predictive factors. Results: SL 
patients received a longer duration of FL compared with BSC 
patients with median duration being 16.0 weeks (range, 8.0 
to 26.0 weeks) and 8.0 weeks (range, 4.0 to 16.0 weeks), 
respectively (p<0.001). When the SL group was stratified by 
their modified overall survival (mOS) (longer and shorter than 
6 months), we found significant differences for several clini-
cal factors, namely, metastasis to the peritoneum (p<0.001), 
number of metastases (p<0.001), thrombotic events 
(p=0.003), and level of carbohydrate antigen 19-9 (CA19-
9; p=0.011). In multivariate analysis, more than one site of 
metastasis, occurrence of thrombotic event during FL, and a 
CA19-9 level above 90 U/mL were significant independent 
prognostic factors for mOS in the SL group (p<0.05). When 
an attempt was made to devise a prognostic nomogram, 
Harrell’s C-index of the final prognosis prediction model was 
0.62. Conclusions: SL may be beneficial for patients with-
out peritoneal metastasis or thrombotic events who have a 
single metastasis and a level of CA19-9 less than 90 U/mL. 
This prognostic nomogram can be used to predict mOS be-
fore the administration of SL after the failure of gemcitabine-
based FL. (Gut Liver 2020;14:135-143)
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INTRODUCTION
Pancreatic cancer is a leading cause of cancer death world-
wide with an estimated 5-year survival rate of 5% to 6%.1,2 
From 1990s, gemcitabine has been positioned as the backbone 
drug for the first-line chemotherapy (FL) in unresectable pan-
creatic cancer, proving the improvement of overall survival (OS).3 
Despite the substantial development in palliative chemothera-
pies, the median OS is still less than 8 months with frequent 
resistance in FL.4,5 Numerous second-line chemotherapies (SLs) 
have been attempted to improve OSs of the patients enfacing 
the treatment failure of gemcitabine based FL.6 Currently, the 
CONKO-003 study presented the OFF regimen including oxali-
platin, folinic acid and 5-fluorouracil (5-FU), as an effective SL 
therapy after gemcitabine refractory treatment, demonstrating 
significant improvement in OS.7 However, there are no other 
large randomized studies to establish the consensus of SL after 
disease progression of FL treatment. Furthermore, there is no 
evidence proving the superiority of SL with best supportive care 
(BSC) after failure of first line treatment failure.8,9 
Our study was to analyze the clinical characteristics of pa-
tients who have received SL or discontinued salvage chemo-
therapy and went on with BSC after FL treatment. The primary 
endpoint was to evaluate clinical characteristics affecting the 
benefits from receiving SL comparing to BSC. The second end-
point of our study was to establish a prognostic scoring system 
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for an optimal decision of proceeding SL after the failure of 
gemcitabine-based FL. 
MATERIALS AND METHODS
All patients with histologically proven pancreatic adenocar-
cinoma treated at Gastroenterology Unit of Yonsei University 
Hospital, Seoul, Republic of Korea, between January 2010 and 
December 2015 were involved in the development cohort. Pa-
tients were considered eligible for medical evaluation of SL in-
dication if they had received one previous line of gemcitabine-
based FL, including gemcitabine-based adjuvant chemotherapy 
in patients who had undergone curative resection. The external 
validation cohort included patients with proven pancreatic ad-
enocarcinoma who received gemcitabine-based FL in the same 
institution as the development cohort between January 2016 
and December 2016. All clinical, biological, and radiological pa-
rameters of the data were measured at the beginning of SL or at 
the end of FL for patients who proceeded with BSC. Treatment 
outcomes were retrospectively collected from medical records.
This is a retrospective study that only involves the collection 
of existing clinical data and medical records. The research did 
not include any direct or indirect identification information of 
study participants. The study participants’ privacy, confidential-
ity and anonymity were guaranteed. The rights or interests of 
study participants were not violated. The risk of the study par-
ticipant was not greater than the minimum risk. Because of the 
retrospective nature of the study, the informed consent of each 
participant was not available. According to the guidelines for 
the review of major ethical issues in Republic of Korea’s clinical 
research, this type of study meets the conditions of exemption 
from formal ethics approval and written informed consent.
OS was calculated from the date of initiation of FL to the date 
of death from any cause. Modified OS (mOS) was calculated 
from the date of first administration of SL to the date of death 
from any cause. For patients who only received FL and went on 
with BSC after progression, mOS was measured from the end of 
FL to death of any cause. For patients with history of curative 
operation following cancer progression after gemcitabine-based 
adjuvant chemotherapy, mOS was measured from the initiating 
date of first line palliative chemotherapy to the date of death 
from any cause.
Median value (interquartile range) and frequency (percentage) 
were provided for the description of continuous and categorical 
variables, respectively. Medians and proportions were compared 
using the Student t-test and chi-square test (or Fisher exact test, 
if appropriate), respectively. The Cox proportional hazard mod-
els were performed to estimate hazard ratio and 95% confidence 
interval (CI) for prognostic factors associated with mOS. The 
association of baseline parameters of mOS was first assessed 
by dividing the patient into two groups by mOS; less than 6 
months and more than 6 months. Additionally, baseline param-
eters of mOS was assessed by univariate Cox analyses, and then 
parameters with p-values of less than 0.05 were entered into the 
final multivariable Cox regression model, after considering col-
linearity among variables with a correlation matrix. 
Sensitivity analysis to explore the reliability of the final 
prognosis predictive model was performed with a stratified and 
a frailty approach by using a random component for the haz-
ard function based on the regimen, and with a full-model and 
forward procedure. Accuracy of the final predictive model was 
verified regarding the discrimination parameter. The predictive 
value and the discrimination ability of the final model were as-
sessed internally and externally with the Harrell’s concordance 
index (C-index) and incremental area under the curve (iAUC). 
The prognostic score was constructed with total points calcu-
lated by the nomogram. To identify risk groups and determine 
their survival benefit with SL, the Kaplan-Meier method with 
log-rank tests was used for comparisons between prognostic 
subgroups classified by the nomogram scoring.
All analyses were performed using SPSS version 23.0 (IBM 
Corp., Armonk, NY, USA) and R software version 2.15.2 (R De-
velopment Core Team, Vienna, Austria; http://www.r-project.
org). Two-sided p-values less than 0.05 were considered statisti-
cally significant.
RESULTS 
1. Characteristics of SL group compared to BSC group after 
FL failure
The median OS of SL patients versus BSC patients was 40 
weeks (range, 28.0 to 56.0 weeks) versus 16.0 weeks (range, 12.0 
to 32.0 weeks; p<0.001). The median OS after the progression 
of FL of SL group (mOS) was 20.0 weeks (range, 12.0 to 32.0 
weeks; p<0.001). The median duration of BSC of FL only group 
after progression of FL (mOS) was 8.0 weeks (range, 4.0 to 16.0 
weeks; p<0.001). 
There was significant difference in sex between two groups 
(evaluable in 501 patients; male: SL 47.3% vs BSC 62.9%; 
p=0.001). The Eastern Cooperative Oncology Group (ECOG) 
performance status was significantly higher in SL patients at 
the initiation of palliative SL chemotherapy (evaluable in 501 
patients; ECOG 0: SL 83.7% vs BSC 61.7%; p<0.001). There was 
a significant difference in primary tumor localization between 
two groups (evaluable in 501 patients; localization at head: SL 
52.2% vs BSC 38.3%; p=0.002).
A significantly higher number of SL patients received longer 
duration of FL (evaluable in 501 patients; SL group median 
16.0 weeks [range, 8.0 to 26.0 weeks] vs BSC median 8.0 weeks 
[range, 4.0 to 16.0 week]; p<0.001). Significantly more patients 
in the SL group were diagnosed with metastasis to the lung (SL 
20.4% vs BSC 10.5%; p=0.003) and peritoneum (SL 32.7% vs 
BSC 40.8%; p=0.001). 
There were no differences detected between SL group and 
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BSC group regarding age, metastatic lesion (liver, bone, distant 
lymph node and other sites including adrenal gland at spleen), 
number of metastasis after FL progression, preexisting diabe-
tes, thrombosis event during FL and body mass index (BMI). 
Moreover, there was no significant difference in tumor markers 
carbohydrate antigen 19-9 (CA19-9) (Table 1).
2. Characteristics of mOS above 6 months and mOS below 
6 months in SL group 
SL patients were divided into two groups depending on the 
mOS duration: mOS less than 6 months and greater than 6 
months. The median mOS of the mOS less than 6 months group 
was 12.0 weeks (range, 8.0 to 24.0 weeks). The median mOS of 
the mOS greater than 6 months group was 36.0 weeks (range, 
28.0 to 52.0 weeks). 
In analysis of 245 patients with metastasis before initiation 
of SL, single metastasis was more common in the mOS greater 
than 6 months group (mOS less than 6 months group 42.0% 
vs mOS greater than 6 months group; p=0.001) and multiple 
metastasis was more common in the mOS less than 6 months 
group (mOS less than 6 months group 58.0% vs mOS greater 
than 6 months group; p<0.001).
Peritoneal metastasis was significantly more frequent in mOS 
below 6-month group (evaluable in 245 patients; peritoneal me-
tastasis: mOS less than 6 months group 43.5% vs mOS greater 
more than 6 months group 18.7%; p<0.001).
Table 1. Baseline Characteristics of BSC Patients and SL Patients after FL Failure 
Characteristic BSC (n=256) SL (n=245) p-value
Male sex 161 (62.9) 116 (47.3) 0.001
Age, yr  64.0 (55.0–71.0)   62.0 (55.5–69.0) 0.151
ECOG 0 158 (61.7) 205 (83.7) <0.001
Tumor localization 0.002
   Head  98 (38.3) 128 (52.2)
   Body and tail  142 (55.5)  98 (40.0)
   Overlapping 16 (6.3) 19 (7.8)
Metastatic lesion
   Liver 174 (68.0) 168 (68.6) 0.924
   Lung 27 (10.5) 50 (20.4) 0.003
   Bone 21 (8.2) 11 (4.5) 0.102
   Others 24 (9.4) 18 (7.3) 0.426
   Distant lymph node 35 (13.7) 50 (20.4) 0.056
   Peritoneum 123 (40.8) 80 (32.7) 0.001
No. of metastasis 0.929
   Single 138 (53.9) 131 (53.5)
   Multiple 118 (46.1) 114 (46.5)
FL duration, wk   8.0 (4.0–16.0)  16.0 (8.0–26.0) <0.001
   OS   16.0 (12.0–32.0)  40.0 (28.0–56.0) <0.001
   mOS  8.0 (4.0–16.0)  20.0 (12.0–32.0) <0.001
Diabetes mellitus 81 (31.6) 95 (38.8) 0.111
Thrombosis 30 (11.7) 31 (12.7) 0.786
CA19-9 ≥90.0 U/mL 193 (75.4) 157 (64.1) 0.006
BMI, kg/m2   22.2 (20.32–23.60)   22.7 (21.95–23.82) 0.335
SL type - -
   FOLFIRINOX 90 (36.7)
   FOLFOX 29 (11.8)
   Capecitabine+oxaliplatin 98 (40.0)
   FEP 28 (11.4)
Data are presented as number (%) or median (interquartile range).
BSC, best supportive care; SL, second-line chemotherapy; FL, first-line chemotherapy; ECOG, Eastern Cooperative Oncology Group; OS, overall 
survival; mOS: modified OS; CA19-9, carbohydrate antigen 19-9; BMI, body mass index; FOLFIRINOX, 5-FU+folinic acid+irinotecan+oxaliplatin; 
FOLFOX, folinic acid+fluorouracil+oxaliplatin; FEP, folinic acid+etoposide+cisplatin.
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Thrombotic events were significantly more frequent in the 
mOS less than 6 months group (evaluable in 245 patients; 
thrombotic event: mOS less than 6 months group 18.1% vs 
mOS greater than 6 months group 5.6%; p=0.003).
CA19-9 measured after FL progression was significantly 
higher in the mOS less than 6 months group (evaluable in 245 
patients; CA19-9 ≥90 U/mL: mOS less than 6 months group; 
71.0% vs mOS greater than 6 months group; 55.1%; p=0.011).
There were no significant differences detected between two 
groups regarding sex, age, ECOG performance status, primary 
tumor localization, metastatic lesion besides peritoneum, FL 
duration, preexisting diabetes, BMI, curative operation and regi-
men type of SL (Table 2).
3. Univariate and multivariate analysis for mOS in SL group 
Univariate analysis revealed ECOG performance status, perito-
neal metastasis, number of metastasis, FL duration, thrombotic 
event, CA19-9 level above 90 U/mL and BMI were significant 
independent prognostic factors for mOS (p<0.05). Therefore, the 
factors were included in the multivariate analysis.
In the multivariate analysis, more than one site of metastasis 
lesion, thrombotic event during FL and CA19-9 level above 90 
U/mL were significantly independent prognostic factors for mOS 
for all 245 patients in SL group (p<0.05) (Table 3).
Table 2. Baseline Characteristics of Patients with mOS Less Than 6 Months and Greater Than 6 Months in the SL Group 
Characteristic mOS 6 months below (n=138) mOS 6 months above (n=107) p-value
Male sex 65 (47.1) 55 (51.4) 0.522
Age, yr 64.0 (56.0–69.0)  61.0 (55.0–68.0) 0.076
ECOG 0 110 (79.7) 95 (88.8) 0.145
Tumor localization 0.451
   Head 68 (49.3) 60 (56.1)
   Body and tail   60 (43.5) 38 (35.5)
   Overlapping 10 (7.2) 9 (8.4)
Metastatic lesion
   Liver 101 (73.2) 67 (62.6) 0.096
   Lung 26 (18.8) 24 (22.4) 0.525
   Bone 4 (2.9) 7 (6.5) 0.218
   Other 10 (7.2) 8 (7.5) 1.000
   Distant lymph node 29 (21.0) 21 (19.6) 0.873
   Peritoneum 60 (43.5) 2 0(18.7) <0.001
No. of metastasis <0.001
   Single 58 (42.0) 73 (68.2)
   Multiple 80 (58.0) 34 (31.8)
FL duration, wk
   OS 16.0 (8.0-24.0)  20.0 (12.0-32.0) 0.108
   mOS 12.0 (8.0-24.0)  36.0 (28.0-52.0) <0.001
Diabetes mellitus 52 (37.7) 43 (40.2) 0.694
Thrombosis 25 (18.1) 6 (5.6) 0.003
CA19-9 ≥90.0 U/mL 98 (71.0) 59 (55.1) 0.011
BMI, kg/m2   22.5 (20.90–23.67)   23.4 (22.20–24.30) 0.187
Curative operation 36 (26.1) 28 (26.2) 0.989
Second line type 0.217
   FOLFIRINOX 45 (32.6) 46 (43.0)
   FOLFOX 15 (10.9) 13 (12.1)
   Capecitabine+Oxaliplatin 63 (45.7) 35 (32.7) 
   FEP 15 (10.9) 13 (12.1)
Data are presented as number (%) or median (interquartile range).
mOS, modified overall survival; SL, second-line chemotherapy; ECOG, Eastern Cooperative Oncology Group; FL, first-line chemotherapy; OS, 
overall survival; CA19-9, carbohydrate antigen 19-9; BMI, body mass index; FOLFIRINOX, 5-FU+folinic acid+irinotecan+oxaliplatin; FOLFOX, 
folinic acid+fluorouracil+oxaliplatin; FEP, folinic acid+etoposide+cisplatin.
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4. Prognostic nomogram and prediction of the survival ben-
efit of SL 
The prognostic nomogram was devised with all statistically 
significant independent factors from the analysis of mOS groups 
divided by duration of 6 months (Fig. 1). Number of metastasis 
lesion, peritoneal metastasis, thrombotic event during FL and 
CA19-9 were the final determinants integrated to the nomo-
gram. The prognostic score was based on the total number of 
points obtained from the nomogram. 
5. Confirmation of the prediction model with prognostic 
subgroups
We identified three prognostic subgroups with the nomogram 
scoring: “good” prognosis (score 0–60), “intermediate” progno-
sis (score 116–160) and “poor” prognosis (score 176–276). Good 
prognosis group included: none of the four determinants (score 
0), only peritoneal metastasis (score 58), only single metastasis 
(score 58), only CA19-9 above 90 U/mL (score 60). Poor prog-
nosis group included any three determinants together (scores 
176 and 218) or all four significant factors included (maximum 
Table 3. Univariate and Multivariate Analyses of the mOS in the SL Group (n=245) 
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Sex 1.059 (0.822–1.363) 0.659 - -
Age 1.011 (0.997–1.026) 0.121 - -
ECOG 
   0 Reference Reference Reference Reference
   ≥1 0.400 (0.164–0.978) 0.044 1.364 (0.933–1.992) 0.109
Tumor localization - -
   Head Reference 0.057
   Body and tail 0.812 (0.499–1.322) 0.403
   Overlapping 1.128 (0.690–1.845) 0.631
Metastatic lesion - -
   Liver 1.232 (0.962–01.57) 0.099
   Lung 1.024 (0.764–1.372) 0.876
   Bone 0.978 (0.548–1.747) 0.941
   Other 0.830 (0.536–1.285) 0.404
   Distant lymph node 0.994 (0.744–1.328) 0.967
   Peritoneum 1.622 (1.236–2.127) <0.001 1.253 (0.924–1.698) 0.147
No. of metastasis
   Single 0.621 (0.481–0.802) <0.001 0.694 (0.520–0.926) 0.013
   Multiple Reference Reference Reference Reference
SL type
   FOLFIRINOX Reference Reference Reference Reference
   FOLFOX 0.776 (0.506–1.190) 0.245 1.605 (1.023–2.518) 0.040
   Capecitabine+Oxaliplatin 1.151 (0.680–1.949) 0.601 1.710 (1.233–2.372) 0.001
   FEP 1.381 (0.904–2.110) 0.135 1.500 (0.955–2.355) 0.078
FL duration 0.988 (0.979–0.997) 0.012 0.991 (0.982–1.001) 0.074
Diabetes mellitus 0.830 (0.655–1.051) 0.123 - -
Thrombosis 1.789 (1.219–2.626) 0.003 1.391 (0.929–2.082) 0.035
CA19-9 <90.0 U/mL 0.662 (0.504–0.868) 0.003 1.184 (0.881–1.591) 0.025
CA19-9 ≥90.0 U/mL Reference Reference Reference Reference
BMI 0.926 (0.861–0.995) 0.037 0.940 (0.875–1.010) 0.090
Curative operation 0.766 (0.568–1.033) 0.081 - -
mOS, modified overall survival; SL, second-line chemotherapy; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative On-
cology Group; FOLFIRINOX, 5-FU+folinic acid+irinotecan+oxaliplatin; FOLFOX, folinic acid+fluorouracil+oxaliplatin; FEP, folinic 
acid+etoposide+cisplatin; FL, first-line chemotherapy; CA19-9, carbohydrate antigen 19-9; BMI, body mass index.
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score 276). The expected survival after the FL failure represented 
as median mOS was 28.0 weeks (95% CI, 25.2 to 30.8) in good 
prognosis group, 18.0 weeks (95% CI, 15.8 to 210.2) in interme-
diate prognosis group, and 12.0 weeks (95% CI, 10.7 to 13.3) in 
poor prognosis group (p<0.001). Such grouping achieved a clear 
separation of the Kaplan-Meier curves (Fig. 2). 
6. Internal validation and external validation of the final 
nomogram
The discrimination ability of the final scoring model devel-
oped in the main analysis was internally confirmed: the Har-
rell’s C-index was 0.620 and the iAUC curve of the development 
cohort was 0.619. Data of the four baseline parameters that 
were required for the nomogram calculation was available for 
123 patients from the external validation cohort: the Harrell’s C-
index was 0.560 and the iAUC curve of the external validation 
cohort was 0.562 (Fig. 3). 
DISCUSSION
Generally, pancreatic cancer progression is very rapid and pa-
tient’s performance status falls even more rapidly not enough to 
be suitable for any salvage chemotherapy when the FL is turned 
out to be ineffective.10,11 Due to the aggressive manner of the 
disease and the toxicity of chemotherapy, consideration for SL 
should be more cautious of the risk and benefit.12 
Current guideline for advanced pancreatic cancer recom-
mends SL after the FL failure, even though the benefit of SL 
remains to be controversial.13 The CONKO-003 study, an open 
randomized phase 3 study, proved that the combination of ox-
aliplatin, 5-FU, and folinic acid (OFF regimen) after previous 
gemcitabine-based chemotherapy was superior to BSC in terms 
of PFS (13 weeks vs 9 weeks) and OS (26 weeks vs 13 weeks).7 
However, there is no more concrete evidence to support the 
usefulness of SL for gemcitabine-refractory advanced pancreatic 
cancer.1,13 
Considering that the clinical benefit of currently available SL 
is marginal, it is very important to find the clinical parameters 
for determining the potential benefit of the salvage treatment 
when the patients are enfaced the failure of FL.14-16 Maréchal et 
al.17 reported that patient’s performance status and initial albu-
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Fig. 1. Prognostic nomogram to predict individual modified overall survival (mOS) probability. Prognostic nomogram to predict individual mOS 
probability at the beginning of second-line chemotherapy in patients with advanced pancreatic cancer. First, the points associated with each of 
the four prognostic factors are obtained via upward vertical translation of the patient’s variable value to the line labeled “Points.” Next, the points 
are summed and the corresponding total number is reported as a dot on the line labeled “Total points.” A vertical line is then drawn downward 
from the total point dot to obtain the mOS prediction at the intersection with the “3-,” “6-,”and “9-month survival probability” lines. 
No peritoneal metastasis: 0, peritoneal metastasis: 1; single metastatic lesion: 0, multiple metastatic lesions: 1; No thrombotic event: 0, thrombotic 
event: 1; carbohydrate antigen 19-9 (CA19-9) <90 U/mL: 0, CA19-9 ≥90 U/mL: 1.
Fig. 2. Kaplan-Meier curves of modified overall survival (mOS) for 
the prognostic subgroups “good-intermediate-poor” in the develop-
ment cohort.
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min level were independent prognostic factors in chemotherapy 
naive and gemcitabine-refractory patients with advanced pan-
creatic cancer. Petrelli et al.18 suggested the responsiveness to 
the FL with gemcitabine was predictive factor for SL with OFF 
in advanced pancreatic cancer. CA19-9 also was suggested as 
one of the important prognostic markers for SL.7,19-21 
In this study, we tried to develop a simplified and useful 
prognostic model that could clinically predict which patients 
can have the benefit of SL from the retrospective analysis of 
single center cohort data. Our study identified prognostic factors 
influencing the survival of advanced pancreatic cancer patients 
after the progression of FL. The significant factors depending 
on the mOS were peritoneal metastasis, number of metastatic 
lesions, CA19-9 level and thrombotic event. Based on these 
findings, we made a nomogram scoring system. Despite the fact 
that the Harrell’s S-index and iAUC internal validation index of 
the nomogram were not so powerful, this scoring system allows 
reliable differentiation into three prognostic groups (good, inter-
mediate, and poor) which demonstrate clear differences in mOS. 
Patients in the poor prognosis group had a median mOS of 
about 12 weeks, and those in the good prognosis group of about 
28 weeks, demonstrating a difference of about 16 months.
Despite the fact that pragmatic parameters are already fre-
quently used in decision making for the initiation of SL, our 
final nomogram presents simplicity compared to previous ap-
proach with multiple and complex variables of the scoring sys-
tem. In addition to helping the decision-making process for cli-
nicians, this nomogram may be beneficial for selecting patients 
for SL. Moreover, with this prognostic monogram, the develop-
ment of risk adapted therapies for pancreatic cancer in palliative 
SL management could be also considered in the different risk 
groups identified by the scoring system. 
There are several points which provide differentiation 
among other similar studies. The inclusion period in our 
study was long enough, from 2010 to 2015, to include sen-
sational regimens introduced in the field. This time period is 
very important in the era of pancreatic cancer since clinical 
practices have changed with the approval of the 5-FU+folinic 
acid+irinotecan+oxaliplatin (FOLFIRINOX) and gemcitabine 
plus nab-paclitaxel chemotherapy.22 Our study evaluated a large 
cohort population including patients treated with original or 
modified FOLFIRINOX regimen in SL, which was approved in 
2011 and widely available from 2014.23 Parameters used in the 
model are clinically approached, simple to collect for clinicians, 
and consistent with the previous models devised. Internal vali-
dation was demonstrated to prove the satisfactory performance 
and validity of the nomogram. Our prognostic nomogram was 
externally validated through patient group in 2016 of Yonsei 
University Hospital. Therefore, our final prognostic nomogram 
made an attempt to confirm the reliability in the era of new, 
highly efficient treatment regimens for advanced pancreatic 
cancer. Few similar prognostic models suggested currently have 
limitation of heterogeneity in FL. However, our study made as-
sess to similar prognostic factors in homogenous gemcitabine-
based FL patient groups.24 
However, there are limitations in generalizing our prognostic 
nomogram due to the retrospective nature of the study. Due to 
the slightly low C-index of the nomogram, the predictive ability 
of the scoring system is not fully qualified to be used in gen-
eral practice yet. Moreover, the external validation also showed 
low predictive ability. Hopefully, with the significant variables 
from the analysis, the predictive ability will improve with more 
data sets. External validation in different hospitals and in other 
countries will definitively confirm the worldwide relevance of 
the model in the future. Thus, the prognostic usefulness of our 
nomogram needs to be confirmed through a large prospective 
validation in the future.
Many oncologic approaches are currently made to figure out 
which patients truly benefit from receiving SL on molecular 
basis but little is being researched on clinical basis.25 There is 
Fig. 3. Internal validation iAUC (A) and external validation iAUC (B) of the prognostic nomogram. 
iAUC, incremental area under the curve.
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no worldwide consensus of clinical parameter scoring system 
available to support the physician’s decision to go on with SL 
or give up palliative chemotherapy and start BSC.24 Despite the 
limitations mentioned above, this study with our prognostic 
nomogram based scoring system may help to develop strategies 
to identify patients who can obtain real benefit from SL after 
progression of gemcitabine-based FL.
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